Added to YB: 2026-06-09
Pitch date: 2026-06-05
CMPX [bullish]
Compass Therapeutics, Inc.
-0.98%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
Market Cap
$367.4M
Pitch Price
$2.04
Price Target
6.35 (+198%)
Dividend
N/A
EV/EBITDA
-2.48
P/E
-5.08
EV/Sales
N/A
Sector
Biotechnology
Category
value
Should you buy the dip on Compass Therapeutics ($CMPX)?
CMPX: Clinical-stage onco biotech, $2.13 vs $6.35 PT (+198%). Stock -65% on COMPANION-002 OS miss (HR 1.05) for tovecimig in 2L biliary cancer, but PFS HR 0.44 (p<0.0001) & tripled ORR clean; 54% crossover corrupted OS. $195M cash floor=current px. Late-2026 pre-BLA FDA meeting key catalyst. rNPV SOTP $934M. Bear: new trial req'd, $1.00-1.20.
Read full article (17 min)